Defining and Treating High Risk HR-positive/HER2-Negative Early Breast Cancer

Download Transcript

Hear perspectives of real-world evidence of recurrence risk with endocrine therapy alone, the prognostic impact of high-risk disease, and clinical evidence supporting adjuvant CDK4/6 inhibitors from Seth Wander, MD, PhD, of Harvard Medical School and Massachusetts General Hospital, and Kathryn Post, PhD, RN, ANP-BC, of Harvard Medical School and Mass General Brigham Cancer Institute.